Janux Therapeutics Inc (JANX)
48.76
+2.26
(+4.86%)
USD |
NASDAQ |
Nov 22, 13:40
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 2.559B |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | 434.5% |
Valuation | |
PE Ratio | -- |
PE Ratio (Forward) | Upgrade |
PS Ratio | 191.36 |
Price to Book Value | 3.900 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | 0.00 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | -- |
Profile
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to treat patients suffering from cancer. |
URL | https://www.januxrx.com |
Investor Relations URL | N/A |
HQ State/Province | California |
Sector | Health Care |
Industry | Biotechnology |
Equity Style | Small Cap/Growth |
Next Earnings Release | May. 08, 2025 (est.) |
Last Earnings Release | Nov. 06, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Ratings
Profile
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to treat patients suffering from cancer. |
URL | https://www.januxrx.com |
Investor Relations URL | N/A |
HQ State/Province | California |
Sector | Health Care |
Industry | Biotechnology |
Equity Style | Small Cap/Growth |
Next Earnings Release | May. 08, 2025 (est.) |
Last Earnings Release | Nov. 06, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |